anonymous
Guest
anonymous
Guest
Tildrakizumab is not recommended, within its marketing authorisation, for treating moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate.
This is from appraisal document posted on NICE website
This is from appraisal document posted on NICE website